Grifols Adding $210M Expansion To Clayton Campus
|Aerial view shows the scope of the sprawling 233-acre Clayton campus of Grifols, which will soon get two more buildings as the company invests $210 million more.|
Blood therapeutics company Grifols said it will invest $210 million to build two new facilities at its Clayton campus.
The added buildings are being announced less than a year after the Spanish company began production in a $370 million Clayton manufacturing addition, which the company said brought in 200 new workers and added several therapeutic targets to the company's offerings.
Grifols said it would start construction on a new $90 million plasma fractionation plant in the first quarter of 2017, with a target of bringing it into production in 2022. The second building is to be a $120 million purification plant for intravenous immunoglobin, to come into production in late 2021.
The company did not announce how many new jobs might result from the expansion. The company said at the time its recent 155,000-square-foot expansion was completed that it resulted in 1,850 employees in Johnston County, making it the county’s largest employer.
Grifols therapies are made from proteins derived from blood plasma purchased from collection centers around the country. Employees at the Clayton site extract the proteins through a process called fractionation.
Grifols' newest addition in Clayton, the 155,000-square-foot North Fractionation Facility, will be joined by two more buildings during the next few years, an additional $210 million investment. -- Photos courtesy of Grifols
The products are used to treat rare and chronic diseases such as immune deficiencies, hemophilia, genetic emphysema and neurological disease.
Grifols became a major North Carolina life science presence in 2011 with its $4 billion acquisition of Research Triangle Park-based Talecris Biotherapeutics. Grifols owns 233 acres in Clayton, much of it yet to be developed. That gives the North Carolina campus an advantage over another Grifols fractionation campus in Los Angeles.
Grifols is the largest Spanish company with a U.S. footprint. It has more than 10,000 U.S. workers, most of them in North Carolina. The company also has a major R&D facility in Research Triangle Park.
The company also said today it would be investing $150 million in two new European facilities – an $85 million expenditure in Ireland and $65 million in Spain.
Grifols is one of the world’s leading companies in the manufacture of plasma-based medicines, with direct commercial presence in 30 countries and sales in more than 100.